Home/ Stocks/ AVBP

ArriVent BioPharma, Inc. Common Stock

AVBP XNAS

$29.50 +0.65 (+2.25%) ▲ 15-min delayed

Open

$28.91

High

$30.05

Low

$28.66

Volume

271.0K

Market Cap

$1.37B

About ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 77 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-166,308,000	$-4.32
FY 2025	$0	$-166,308,000	$-4.32
Q3 2025	$0	$-34,978,000	$-0.83
Q2 2025	$0	$-31,399,000	$-0.90

Related Market News

No specific coverage for AVBP yet. Check out our latest market news or earnings calendar.

Get AVBP Alerts

Stay ahead with breaking news, price alerts, and expert analysis on ArriVent BioPharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.